Publication: Photodynamic Therapy, Photobiomodulation and Acetonide Triamcinolone 0.1% in the Treatment of Oral Lichen Planus: A Randomized Clinical Trial
Authors
Salinas-Gilabert, Carmen ; Gomez Garcia, Francisco ; Galera Molero, Fe ; Vander Beken, Seppe ; Lopez Jornet, Pia ; Pons-Fuster López, Eduardo
item.page.secondaryauthor
item.page.director
Publisher
MDPI
publication.page.editor
publication.page.department
DOI
https://doi.org/10.3390/pharmaceutics15010030
item.page.type
info:eu-repo/semantics/article
Description
© 2022. The authors. This document is made available under the CC-BY 4.0 license http://creativecommons.org/licenses/by /4.0/
This document is the published version of a published work that appeared in final form in
Pharmaceuties.
Abstract
Objective: To evaluate the efficacy of photodynamic therapy (PDT) and photobiomodulation
(PBM) in the treatment of oral lichen planus (OLP) in comparison with the use of topical
corticosteroids. Material and methods: Sixty patients with OLP were randomized to three groups:
group 1 photodynamic therapy applied once a week for four sessions, with orabase cream; group
2 low-power laser application with orabase cream; and group 3 inactive laser with triamcinolone
acetonide 0.1%. Patient pain was evaluated, and the Thongprasom severity score, the Oral Health
Impact Profile-14 (OHIP-14), and the Hamilton anxiety and depression scale at one and three months
of follow-up. (ClinicalTrials.gov Identifier: NCT05127083). Results: Pain decreased significantly over
time in all groups, though the symptoms relapsed over follow-up at one and three months in group
3. The OHIP-14 score improved significantly in groups 1 and 2 (p < 0.05), and this improvement
was maintained after three months. Lesion resolution evaluated by the Thongprasom score at one
month showed significant differences between groups 1 and 3 (p = 0.032) and between groups 2 and
3 (p = 0.024). Conclusions: Photodynamic therapy and photobiomodulation once a week for four
weeks are safe and non-invasive treatment options, with the important advantage of lacking adverse
effects. Further studies are needed to confirm it.
publication.page.subject
Citation
Pharmaceutics 2023, 15, 30.
item.page.embargo
Collections
Ir a Estadísticas
Este ítem está sujeto a una licencia Creative Commons. http://creativecommons.org/licenses/by/4.0/